A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort

被引：0
作者：
Yuan, Li
Shu, Pei
Li, Xiaoyu
Li, Guiling
Zhang, Keqiang
Lai, Lin
Hong, Jinsheng
Huang, Chu-Ying
Wang, Yongsheng
Xie, Hui
Zheng, Li
Zhou, Qi
机构：
[1] Chongqing Univ Canc Hosp, Chongqing, Peoples R China
[2] Sichuan Univ, West China Hosp, Natl Med Prod Adm Key Lab Clin Res & Evaluat Inno, Clin Trial Ctr,State Key Lab Biotherapy, Chengdu, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[4] Hunan Canc Hosp, Changsha, Peoples R China
[5] Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Dept Abdominal Oncol, Enshi, Peoples R China
[6] Fujian Med Univ, Dept Radiotherapy, Ctr Canc, Affiliated Hosp 1, Fuzhou, Peoples R China
[7] Hubei Selenium & Human Hlth Inst, Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Enshi, Peoples R China
[8] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[9] Antengene Corp, Dept Clin Res & Dev, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5509
引用
收藏
页数：1
相关论文
共 50 条
[41]   Preliminary outcomes from a phase 1b/2 study of the highly potent PI3KmTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer Free [J].
Li, Guiling ;
Huang, Ai ;
Yang, Qin ;
Ding, Yanhua ;
Li, Dapeng ;
Wei, Shuqing ;
Li, Quan ;
Zheng, Zhong ;
Lai, Shuzhen ;
Lou, Hanmei ;
Sun, Yang ;
Huang, Jiaming ;
Tan, Husheng ;
Jia, Xiao ;
Wei, Wei ;
Li, Yongguo ;
Guo, Ye .
CANCER RESEARCH, 2025, 85 (08)
[42]   Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies [J].
Luke, Jason J. ;
Gelmon, Karen ;
Siu, Lillian L. ;
Moreno, Victor ;
Desai, Jayesh ;
Gomez-Roca, Carlos A. ;
Carlino, Matteo S. ;
Pachynski, Russell K. ;
Cosman, Rasha ;
Chu, Quincy Siu-Chung ;
Damian, Silvia ;
Curigliano, Giuseppe ;
Tam, Rachel ;
Wang, Xianling ;
Jeyamohan, Chandrika ;
Wang, Lily ;
Zhu, Li ;
Santucci-Pereira, Julia ;
Greenawalt, Danielle M. ;
Tabernero, Josep .
CLINICAL CANCER RESEARCH, 2025, 31 (11) :2134-2144
[43]   TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies [J].
Howard A. Burris ;
C. D. Kurkjian ;
L. Hart ;
S. Pant ;
P. B. Murphy ;
S. F. Jones ;
R. Neuwirth ;
C. G. Patel ;
F. Zohren ;
J. R. Infante .
Cancer Chemotherapy and Pharmacology, 2017, 80 :261-273
[44]   A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid fumors. [J].
Cohen, R. B. ;
Janne, P. A. ;
Engelman, J. A. ;
Martinez, P. ;
Nishida, Y. ;
Gendreau, S. ;
Wu, B. ;
Felip, E. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[45]   Combination of TORC1/2 and MEK kinase inhibitors in colorectal cancer models [J].
Garcia-Garcia, Celina ;
Serra, Violeta ;
Scaltriti, Maurizio ;
Ibrahim, Yasir ;
Guzman, Marta ;
Jessen, Katti ;
Liu, Yi ;
Rommel, Christian ;
Tabernero, Josep ;
Baselga, Jose .
CANCER RESEARCH, 2011, 71
[46]   Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs [J].
Wei, Bih-Rong ;
Peer, Cody J. ;
Richardson, William J. ;
Hewitt, Stephen M. ;
Figg, William D. ;
Simpson, R. Mark .
FRONTIERS IN VETERINARY SCIENCE, 2022, 9
[47]   Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors. [J].
Parikh, Aparna Raj ;
Radojcic, Vedran ;
Clancy, Myles ;
Brouwer, Susan ;
Kushwaha, Shaliny ;
Huang, Yifan ;
Gabrail, Nashat .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) :TPS227-TPS227
[48]   AZD8055, a combined TORC1/TORC2 inhibitor regulates Mycn protein expression and prevents neuroblastoma growth in vitro and in vivo [J].
Vaughan, Lynsey S. ;
Barker, Karen ;
Webber, Hannah ;
Yann Jamin ;
Robinson, Simon ;
Guichard, Sylvie ;
Chesler, Louis .
CANCER RESEARCH, 2011, 71
[49]   A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors [J].
Scott, Susan C. ;
Farago, Anna ;
Lai, W. Victoria ;
Zahurak, Marianna ;
Rudek, Michelle A. ;
Murray, Judy ;
Carducci, Michael A. ;
Uziel, Tamar ;
Takebe, Naoko ;
Gore, Steven D. ;
Rudin, Charles M. ;
Hann, Christine L. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
[50]   Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors [J].
Lin, Shaoyan ;
Ma, Yuxiang ;
Wang, Yongsheng ;
Yang, Yunpeng ;
Xue, Jinhui ;
Huang, Yan ;
Zhao, Yuanyuan ;
Fang, Wenfeng ;
Hong, Shaodong ;
Zhang, Yang ;
Liu, Qianwen ;
Liu, Guizhong ;
She, Xiaohong ;
Zha, Jiping ;
Zheng, Songmao ;
Li, Yan ;
Luo, Peter ;
Zhang, Li ;
Zhao, Hongyun .
ISCIENCE, 2025, 28 (05)
12345